Laboratory Tests for Depression and Other Psychiatric Disorders — CPB 0306 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0306 — its laboratory tests for depression and psychiatric disorders coverage policy — effective September 26, 2025. Here's what billing teams need to know before submitting claims involving psychiatric lab testing.

This update affects eight CPT codes tied to psychiatric and pain-related lab testing, including the dexamethasone suppression panel (CPT 80420) and six mRNA gene expression profiling codes (CPT 0289U–0294U and 0437U). The policy draws a sharp line: one narrow covered indication, and a long list of codes Aetna will not pay for — regardless of diagnosis.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Laboratory Tests for Depression and Other Psychiatric Disorders
Policy Code	CPB 0306 Aetna
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	Medium
Specialties Affected	Psychiatry, Clinical Laboratory, Pain Management, Revenue Cycle
Key Action	Confirm ordering provider is a psychiatrist and documented indication is psychotic depression vs. schizophrenia differentiation before billing CPT 80420

---

Aetna Psychiatric Lab Test Coverage Criteria and Medical Necessity Requirements 2025

The Aetna dexamethasone suppression test coverage policy is narrow. Very narrow.

Aetna considers the dexamethasone suppression test (DST) medically necessary in one specific situation: when a psychiatrist requests it as an aid to differentiate psychotic depression from schizophrenia. That's the entire covered indication. No other clinical scenario qualifies under this coverage policy.

The clinical rationale is straightforward. Individuals with psychotic depression fail to suppress cortisol after the dexamethasone challenge. Those with schizophrenia show suppression. The DST leverages this physiological difference as a diagnostic tool — but only when ordered by a psychiatrist for this specific differential diagnosis purpose.

Three criteria must all be true for medical necessity to apply:

#	Covered Indication Copy
1	The ordering provider is a psychiatrist — not a primary care physician, not a neurologist, not a general practitioner
2	The purpose is specifically to differentiate psychotic depression from schizophrenia
3	The test ordered is the dexamethasone suppression test itself

Miss any one of these, and you don't have a covered claim. Aetna will deny it.

There is no prior authorization requirement listed in this policy for the covered DST indication — but that doesn't mean prior auth won't be triggered at the plan level. Check the member's specific plan terms before assuming clean submission.

The 48-hour dexamethasone suppression panel bills under CPT 80420. The policy requires free cortisol, urine testing as part of that panel. When you bill CPT 80420, your documentation needs to show the ordering provider's specialty and the specific clinical question being answered — not just a depression diagnosis code.

---

Aetna Psychiatric Lab Test Exclusions and Non-Covered Indications

Six codes in this policy are flat-out not covered. Aetna will not reimburse them for the indications listed in CPB 0306, full stop.

This is where the real financial exposure sits for most billing teams. The mRNA gene expression profiling codes — CPT 0291U (144-gene panel for mood disorders), CPT 0292U (72-gene panel for stress disorders), CPT 0293U (54-gene panel for suicidal ideation), and CPT 0437U (15-biomarker panel for anxiety disorders) — are all listed as not covered under this policy. These are the kinds of tests that look clinically compelling on paper and carry significant list prices. Aetna is not paying for them.

CPT 0290U (pain management, 36-gene mRNA panel) and CPT 0294U (longevity and mortality risk, 18-gene panel) are also listed as not covered. If your lab or practice has been ordering these as part of psychiatric workups, stop and review your Aetna submissions immediately.

The real issue here is that many of these codes represent newer proprietary tests that payers haven't yet accepted as clinically validated. Aetna's position is consistent with how most major payers have treated mRNA gene expression profiling for psychiatric indications — skeptical until larger, peer-reviewed evidence exists. This isn't surprising, but it will sting for any practice that has been billing these codes and expecting reimbursement.

CPT 80420 — the 48-hour dexamethasone suppression panel — is also listed in the "not covered" group. That seems contradictory given the covered indication above. The resolution: the 48-hour panel version (CPT 80420) is not covered, but the covered indication references the DST more broadly. If your lab uses CPT 80420 specifically, verify with your Aetna provider relations contact whether that code is the correct vehicle for the covered DST indication. This is an ambiguity in the policy that you should not try to resolve on your own — loop in your billing consultant before the effective date of September 26, 2025.

---

Coverage Indications at a Glance

---

Aetna Psychiatric Lab Test Billing Guidelines and Action Items 2025

These steps apply before and after the September 26, 2025 effective date.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Psychiatric Lab Tests Under CPB 0306

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Code	Type	Description Copy
DST (verify code)	CPT	Dexamethasone suppression test — covered when ordered by a psychiatrist to differentiate psychotic depression from schizophrenia

Note: The policy supports DST coverage but lists CPT 80420 (48-hour panel) as not covered. Confirm the correct billing code with Aetna directly.

---

Not Covered / Experimental CPT Codes

---

Key ICD-10-CM Diagnosis Codes

---